ArticleESMO real world data and digital oncology2026

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

M E Cazzaniga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.